China Securities Intelligent Finance News: XuanTai Pharmaceutical(688247) announced on August 4 that its products, Isaconazole Sulfate for Injection and Enzalutamide Tablets, which were jointly developed, are expected to be selected in the 12th batch of national centralized drug procurement.
　　According to the announcement, isaconazole sulfate for injection is indicated for the treatment of invasive aspergillosis and invasive mucormycosis in adults; enzalutamide tablets are indicated for the treatment of adult patients with metastatic hormone-sensitive prostate cancer, adult patients with non-metastatic castration-resistant prostate cancer at high risk of metastasis, and adult patients with metastatic castration-resistant prostate cancer who are asymptomatic or have mild symptoms and have not received chemotherapy after failure of androgen deprivation therapy. The proposed winning specifications for isaconazole sulfate for injection are 1 vial/box, and the proposed winning specifications for enzalutamide tablets are 40mg (56 tablets/box) and 80mg (28 tablets/box). The procurement period is from the date of implementation of the winning results to December 31, 2029.
　　The announcement stated that during this centralized procurement cycle, medical institutions will prioritize the use of the winning drugs and ensure the completion of the agreed procurement volume. If the company subsequently signs and implements procurement contracts, it will help further expand product sales, increase market share, promote the development of related products in the domestic market, and enhance the company's brand influence.

https://finance.eastmoney.com/a/202608043830616746.html